Corrigendum to “Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer resistance to cancer immunotherapy” [Drug Resist. Updates, Vol. 90, January 2027, 101473]
Corrigendum to “Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer resistance to cancer immunotherapy” [Drug Resist. Updates, Vol. 90, January 2027, 101473]. // Drug Resistance Updates. – URL: https://www.sciencedirect.com/science/article/pii/S1368764626001378?dgcid=rss_sd_all
Corrigendum to “Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer resistance to cancer immunotherapy” [Drug Resist. Updates, Vol. 90, January 2027, 101473]. Drug Resistance Updates. https://www.sciencedirect.com/science/article/pii/S1368764626001378?dgcid=rss_sd_all
“Corrigendum to “Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer resistance to cancer immunotherapy” [Drug Resist. Updates, Vol. 90, January 2027, 101473].” Drug Resistance Updates.
@article{article43766,
title = {Corrigendum to “Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer resistance to cancer immunotherapy” [Drug Resist. Updates, Vol. 90, January 2027, 101473]},
journal = {Drug Resistance Updates},
url = {https://www.sciencedirect.com/science/article/pii/S1368764626001378?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...